IL-17 cuts to the chase in colon cancer.
Although interleukin-17A (IL-17A) facilitates colon cancer development, its target cells remain elusive. In this issue of Immunity, Wang et al. (2014) now demonstrate that IL-17A receptors on the intestinal epithelium promote progression of APC mutant adenomas associated with IL-6 expression and that IL-17A confers chemotherapy resistance.